These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23266507)

  • 1. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
    Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.
    Cantarini L; Tinazzi I; Caramaschi P; Bellisai F; Brogna A; Galeazzi M
    Int J Immunopathol Pharmacol; 2009; 22(2):551-5. PubMed ID: 19505410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
    Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
    BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
    Alty JE; Monaghan TM; Bamford JM
    Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept in the treatment of intestinal Behcet's disease.
    Ma D; Zhang CJ; Wang RP; Wang L; Yang H
    Cell Biochem Biophys; 2014 Jul; 69(3):735-9. PubMed ID: 24622940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two patients with childhood-onset Behcet's disease successfully treated by anti-tumor necrosis factor therapy].
    Kaneko U; Kishi T; Kikuchi M; Hara R; Shinoki T; Miyamae T; Imagawa T; Mori M; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(3):157-61. PubMed ID: 20601837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
    Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
    J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.
    Arida A; Fragiadaki K; Giavri E; Sfikakis PP
    Semin Arthritis Rheum; 2011 Aug; 41(1):61-70. PubMed ID: 21168186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of etanercept in the treatment of a patient with Behçet's disease.
    Curigliano V; Giovinale M; Fonnesu C; Cerquaglia C; Verrecchia E; Turco S; Manganelli C; Manna R
    Clin Rheumatol; 2008 Jul; 27(7):933-6. PubMed ID: 18330611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
    Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
    BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behçet's disease: a new target for anti-tumour necrosis factor treatment.
    Sfikakis PP
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii51-3. PubMed ID: 12379622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
    Li R; Li X; Zhou H; Shi Y; Wang F; Wu T; Liang J
    Front Immunol; 2023; 14():1205046. PubMed ID: 37287984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
    Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.